Literature DB >> 1763895

Chronic cardiomyopathy and weakness or acute coma in children with a defect in carnitine uptake.

C A Stanley1, S DeLeeuw, P M Coates, C Vianey-Liaud, P Divry, J P Bonnefont, J M Saudubray, M Haymond, F K Trefz, G N Breningstall.   

Abstract

A defect in intracellular uptake of carnitine has been identified in patients with severe carnitine deficiency. To define the clinical manifestations of this disorder, the presenting features of 15 affected infants and children were examined. Progressive cardiomyopathy, with or without chronic muscle weakness, was the most common presentation (median age of onset, 3 years). Other patients presented with episodes of fasting hypoglycemia during the first 2 years of life before cardiomyopathy had become apparent. A defect in carnitine uptake was demonstrable in fibroblasts and leukocytes from patients. The defect also appears to be expressed in muscle and kidney. Concentrations of plasma carnitine and rates of carnitine uptake in parents were intermediate between affected patients and normal control subjects, consistent with recessive inheritance. Early recognition and treatment with high doses of oral carnitine may be life-saving in this disorder of fatty acid oxidation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1763895     DOI: 10.1002/ana.410300512

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  44 in total

1.  Elevated plasma carnitine in the hepatic form of carnitine palmitoyltransferase-1 deficiency.

Authors:  C A Stanley; F Sunaryo; D E Hale; J P Bonnefont; F Demaugre; J M Saudubray
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

2.  Carnitine levels in skeletal muscle, blood, and urine in patients with primary carnitine deficiency during intermission of L-carnitine supplementation.

Authors:  J Rasmussen; J A Thomsen; J H Olesen; T M Lund; M Mohr; J Clementsen; O W Nielsen; A M Lund
Journal:  JIMD Rep       Date:  2015-02-10

Review 3.  Carnitine biosynthesis in mammals.

Authors:  Frédéric M Vaz; Ronald J A Wanders
Journal:  Biochem J       Date:  2002-02-01       Impact factor: 3.857

4.  Carnitine levels in 26,462 individuals from the nationwide screening program for primary carnitine deficiency in the Faroe Islands.

Authors:  Jan Rasmussen; Olav W Nielsen; Nils Janzen; Morten Duno; Hannes Gislason; Lars Køber; Ulrike Steuerwald; Allan M Lund
Journal:  J Inherit Metab Dis       Date:  2013-05-08       Impact factor: 4.982

Review 5.  L-Carnitine.

Authors:  J H Walter
Journal:  Arch Dis Child       Date:  1996-06       Impact factor: 3.791

6.  Primary Carnitine Deficiency Presents Atypically with Long QT Syndrome: A Case Report.

Authors:  Irene De Biase; Neena Lorenzana Champaigne; Richard Schroer; Laura Malinda Pollard; Nicola Longo; Tim Wood
Journal:  JIMD Rep       Date:  2011-09-06

7.  Identification of mutations and evaluation of cardiomyopathy in Turkish patients with primary carnitine deficiency.

Authors:  M Kilic; R K Ozgül; T Coşkun; D Yücel; M Karaca; H S Sivri; A Tokatli; M Sahin; T Karagöz; A Dursun
Journal:  JIMD Rep       Date:  2011-09-22

8.  Heterozygotes for plasmalemmal carnitine transporter defect are at increased risk for valproic acid-associated impairment of carnitine uptake in cultured human skin fibroblasts.

Authors:  I Tein; S DiMauro; Z W Xie; D C De Vivo
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

Review 9.  Inborn errors of energy metabolism associated with myopathies.

Authors:  Anibh M Das; Ulrike Steuerwald; Sabine Illsinger
Journal:  J Biomed Biotechnol       Date:  2010-05-26

10.  Medium chain acylcarnitines dominate the metabolite pattern in humans under moderate intensity exercise and support lipid oxidation.

Authors:  Rainer Lehmann; Xinjie Zhao; Cora Weigert; Perikles Simon; Elvira Fehrenbach; Jens Fritsche; Jürgen Machann; Fritz Schick; Jiangshan Wang; Miriam Hoene; Erwin D Schleicher; Hans-Ulrich Häring; Guowang Xu; Andreas M Niess
Journal:  PLoS One       Date:  2010-07-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.